Αρχειοθήκη ιστολογίου

Τετάρτη 26 Ιουνίου 2019

Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines
New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor,... (Source: Cancer Cell International)

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου